Bicycle sets terms for $65M IPO; Lilly's Cyramza wins fifth cancer approval
→ Oncology company Bicycle Therapeutics, which has put its faith in synthetic short peptides that it believes can deliver a payload better than antibodies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
